Plasminogen Activator Inhibitor Type 1 Antikörper

Antigen: Plasminogen Activator Inhibitor Type 1

Synonyme: PI-7, Pn-1, Spin4, Gdnpn1, SERPINE1, PAI-1

Klonalität: Monoklonal (TJA6)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (IHC)

Produktnummer: ABIN125215

Produktbeschreibung

Weitere Bezeichnung: Plasminogen Activator Inhibitor Type-1

Immunogen: Prokaryotic recombinant protein corresponding to a 250 amino acid portion of the N-terminus of the human PAI-1

Format: Supernatant

Isotyp: IgG2b  (Passende Sekundärantikörper)

Klon: TJA6

Spezifität: This antibody recognizes a 48 kD protein. Plasminogen Activation Inhibitor type 1 (PAI-1) inhibits the conversion of plasminogen to plasmin. It is the principal inhibitor of plasminogen activators t-PA and uPA. PAI-1 is structurally related to the serine protease inhibitor superfamily. PAI-1 protein is overexpressed in a number of malignancies including ovarian cancers and derived cell lines, endometrial cancers, cervical cancer, malignant brain cancers and nasopharyngeal carcinomas.

Anwendungen

Applikationshinweise: Titer/Working Dilution: This antibody may be diluted to a titer of 1:10-1:25 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Positive Control: Breast or Ovarian carcinoma. Cellular localization: Cytoplasmic

Konzentration: 100ug/ml approximately

Buffer: This antibody is supplied as tissue culture supernatant containing sodium azide as preservative.

Lagerung: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Forschungsgebiet: Gerinnung, Proteasen

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Ito, Yonemura, Fujita et al.: "Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer." in: Virchows Archiv : an international journal of pathology, Vol. 427, Issue 5, pp. 487-96, 1996 (PubMed).

Dublin, Hanby, Patel et al.: "Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology." in: The American journal of pathology, Vol. 157, Issue 4, pp. 1219-27, 2000 (PubMed).